Wragge Lawrence Graham & Co
- Litigation / Dispute Resolution (14)
- Company/Commercial (10)
- Intellectual Property (8)
- Employment (7)
- Pharma/Biotech (7)
- Public Sector/Local Authority (5)
- Corporate (4)
- Regulatory and compliance (4)
- Clinical/Medical Negligence (3)
- Information Technology (3)
- In-House (3)
- Competition/EU (2)
- Energy (2)
- Pensions (2)
- Transport (Including aviation and shipping) (2)
- Banking / Finance (1)
- Charities (1)
- Financial services (1)
- Human Rights (1)
- Insurance/reinsurance (1)
- Real Estate (1)
- Telecoms (1)
Sort By: Newest first | Oldest first
‘Swiss’ form patent claims do not need subjective intent for infringement: Court of Appeal rules in Warner-Lambert v Actavis
The English Court of Appeal has issued considered, well-reasoned guidance on the construction of patent claims in ‘Swiss’ form. The decision is likely to have impact well beyond British shores.
£27m award for delays to generic capsules launch is upheld.
Decision clears the way for the launch of ‘generic’ patches...
The Act aims to make support more consistent across England. It will be implemented in two phases.
SPCs and combination products: basic patent on a sole ingredient cannot double as basic patent for combination
On 12 March 2015 the CJEU gave its ruling in Actavis v Boehringer Ingelheim, yet another reference from the UK courts regarding the interpretation of the SPC Regulation 469/2009.
It has never been more crucial for both contracting authorities and suppliers to ensure they are familiar with the changes brought about by the Public Contracts Regulations 2015.
Arnold J has delivered a solution to the issue of a patent with claims in the ‘Swiss form’ but this is unlikely to be the last word in the saga. Life sciences companies – watch this space.
Wragges has advised long-standing client on a three-year drug discovery collaboration agreement with Orca.
Birss J rules on product by process claim construction, extension of scope, added matter and obviousness in Hospira v Genentech.
In Teva v Leo, Mr Justice Birss was asked to decide whether two patents relating to a combined formulation for treatment of psoriasis were valid and infringed.
Wragge Lawrence Graham & Co has advised Formation Capital on its acquisition of NHP for a consideration of £477m.
People have responded to the technological revolution by working longer hours and refusing to leave the office behind even when they can be prised from the desk.
Wragge Lawrence Graham & Co’s public law and regulation expert Ravi Randhawa has been promoted to the role of legal director.
Does the fact that a person is obese mean they are, or could be, ‘disabled’ for the purposes of the Equality Act 2010?
Wragge Lawrence Graham & Co has advised biopharmaceutical company arGEN-X on its first collaboration with Bayer and on a strategic alliance with Shire.
The Court of Appeal has unanimously held that a parent company was not liable for industrial disease suffered by an employee of a subsidiary.
In a recent Technical Board of Appeal decision, the European Patent Office has shed some light upon the boundaries of the prohibition against double patenting.
In Rose, the Administrative Court considered whether a CCG had acted unlawfully in failing to follow guidance issued by NICE.
In February 2013, the European Commission released a draft Network and Information Security Directive.
Allowing independent providers into the NHS Pension Scheme — tackling recruitment issues and facilitating the movement of staff
From 1 April 2014, an independent provider who meets the relevant eligibility criteria will be able to apply to become an employing authority in the NHS Pension Scheme.